Results 231 to 240 of about 252,498 (298)

Regulatory Performance of African National Medicines Regulatory Authorities Achieving WHO Maturity Level 3: Identifying Best Practices. [PDF]

Ther Innov Regul Sci
Owusu-Asante M, Darko DM, Semete-Makokotieia B, Adeyeye CM, Fimbo AM, Rukwata R, Zaki G, Walker S, Salek S.   +8 more
europepmc   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Advancing Compliance with HIPAA and GDPR in Healthcare: A Blockchain-Based Strategy for Secure Data Exchange in Clinical Research Involving Private Health Information. [PDF]

Healthcare (Basel)
Barbaria S, Jemai A, Ceylan Hİ, Muntean RI, Dergaa I, Boussi Rahmouni H.   +5 more
europepmc   +1 more source

Checkpoint blockade and the stem‐like T cell trade‐off

Molecular Oncology, EarlyView.
Stem‐like T cells are key to the success of programmed cell death protein 1 (PD1) blockade, as they sustain long‐term anti‐tumor response by continuously generating effector CD8+ T cells. However, how these cells are maintained in cancer is not fully understood. Hor et al.
Julie M. Mazet, Johanna A. Joyce
wiley   +1 more source

Regulation of phage therapy medicinal products: developments, challenges, and opportunities. [PDF]

Front Cell Infect Microbiol
Fuerst-Wilmes M, Respondek V, Schramm M, Lilienthal N, Buss K, Duechting A.   +5 more
europepmc   +1 more source

Molecular cancer prevention: Intercepting disease

Molecular Oncology, EarlyView.
Oncological practice must evolve, from treating established tumours to proactive cancer interception before clinical manifestation. This will require mechanistic insight into tumour initiation, validated biomarkers of early disease development and redesigned clinical trials, enabling cancer interception to become a core pillar of oncology with the ...
Charlotte Grieco, Tej Pandya, Charles Swanton   +2 more
wiley   +1 more source

Evaluating Data Quality by Proxy: Can We Evaluate All Dimensions of the European Medicines Agency Data Quality Framework for Registry-Based Post-Authorization Safety Studies? [PDF]

Pharmacoepidemiol Drug Saf
Dobay P, Sabidó M.
europepmc   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

India's Unique Legal Framework for Psilocybin Mushroom Research: An Unprecedented Opportunity in Psychiatric Therapeutics. [PDF]

Indian J Psychol Med
Tom A, Reddy BSC, Sethi MIS, Math SB.
europepmc   +1 more source

The complex price setting and reimbursement of non-industrial advanced therapy medicinal products. [PDF]

Health Econ Rev
Špacírová Z, Rejon-Parrilla JC, Espín J.   +2 more
europepmc   +1 more source